The Food and Drug Administration on Wednesday announced approval for Zydelig (idelalisib) to treat patients with chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma.
The Food and Drug Administration’s Center for Drug Evaluation and Research is providing an update to key leadership positions within the Office of Generic Drugs, the agency announced.
AbbVie has finalized a deal for Dublin-based specialty pharmaceuticals company Shire for $54.7 billion.
The Food and Drug Administration on Thursday announced the approval of Ruconest, a recombinant C1-Esterase inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.
FedEx on Thursday was indicted as a co-conspirator for illegally distributing pharmaceuticals sourced from a pair of rogue online pharmacies.
There is “something brewing in Congress” these days, NACDS president and CEO Steve Anderson wrote in a July 16 newsletter to NACDS chain members.
Mylan on Thursday announced that the U.S. District Court for the district of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline in relation to paroxetine CR, the generic version of GSK's Paxil CR.
Current programs to dispose of unused medicines in the home are sufficient, argued representatives of industry in appealing a provision put into place by a San Francisco-area county that would place the burden of recapturing these medicines on the manufacturer.
The National Association of Chain Drug Stores on Tuesday put forward pharmacy-specific solutions as the Senate Finance Committee conducted a hearing on “Chronic Illness: Addressing Patients’ Unmet Needs.”
Former Republican Speaker of the House J. Dennis Hastert last week wrote an editorial for the Washington Times supporting the use of such tamper-resistant pseudoephedrine products as Acura Pharmaceuticals' Nexafed and Westport Pharmaceuticals' Zephrex-D.